Genomic alterations identified by array comparative genomic hybridization as prognostic markers in tamoxifen-treated estrogen receptor-positive breast cancer

Cited 50 time in Web of Science Cited 58 time in Scopus

Han, Wonshik; Han, Mi-Ryung; Kang, Jason Jongho; Bae, Ji-Yeon; Lee, Ji Hyun; Bae, Young Ju; Lee, Jeong Eon; Shin, Hyuk-Jae; Hwang, Ki-Tae; Hwang, Sung-Eun; Kim, Sung-Won; Noh, Dong-Young

Issue Date
BioMed Central
BMC Cancer. 2006 Apr 12;6:92
AdultAgedAntineoplastic Agents, Hormonal/*therapeutic useAntineoplastic Combined Chemotherapy Protocols/administration &dosage/therapeutic useBreast Neoplasms/chemistry/drug therapy/*genetics/radiotherapy/surgeryCarcinoma, Ductal, Breast/chemistry/drugtherapy/*genetics/radiotherapy/secondary/surgeryChemotherapy, AdjuvantChromosomes, Artificial, BacterialCluster AnalysisCombined Modality TherapyCyclophosphamide/administration & dosageDNA, Neoplasm/*geneticsDisease-Free SurvivalEstrogen Receptor Modulators/*therapeutic useFemaleFluorouracil/administration & dosageHumansLife TablesMastectomyMethotrexate/administration & dosageMiddle AgedNeoplasm MetastasisNeoplasm Proteins/analysisNeoplasms, Hormone-Dependent/chemistry/drugtherapy/*genetics/radiotherapy/surgeryOligonucleotide Array Sequence AnalysisPrognosisRadiotherapy, AdjuvantReceptors, Estrogen/analysisTamoxifen/*therapeutic useEstrogensNucleic Acid Hybridization
BACKGROUND: A considerable proportion of estrogen receptor (ER)-positive breast cancer recurs despite tamoxifen treatment, which is a serious problem commonly encountered in clinical practice. We tried to find novel prognostic markers in this subtype of breast cancer. METHODS: We performed array comparative genomic hybridization (CGH) with 1,440 human bacterial artificial chromosome (BAC) clones to assess copy number changes in 28 fresh-frozen ER-positive breast cancer tissues. All of the patients included had received at least 1 year of tamoxifen treatment. Nine patients had distant recurrence within 5 years (Recurrence group) of diagnosis and 19 patients were alive without disease at least 5 years after diagnosis (Non-recurrence group). RESULTS: Potential prognostic variables were comparable between the two groups. In an unsupervised clustering analysis, samples from each group were well separated. The most common regions of gain in all samples were 1q32.1, 17q23.3, 8q24.11, 17q12-q21.1, and 8p11.21, and the most common regions of loss were 6q14.1-q16.3, 11q21-q24.3, and 13q13.2-q14.3, as called by CGH-Explorer software. The average frequency of copy number changes was similar between the two groups. The most significant chromosomal alterations found more often in the Recurrence group using two different statistical methods were loss of 11p15.5-p15.4, 1p36.33, 11q13.1, and 11p11.2 (adjusted p values < 0.001). In subgroup analysis according to lymph node status, loss of 11p15 and 1p36 were found more often in Recurrence group with borderline significance within the lymph node positive patients (adjusted p = 0.052). CONCLUSION: Our array CGH analysis with BAC clones could detect various genomic alterations in ER-positive breast cancers, and Recurrence group samples showed a significantly different pattern of DNA copy number changes than did Non-recurrence group samples.
1471-2407 (Electronic)
Files in This Item:
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Surgery (외과학전공)Journal Papers (저널논문_외과학전공)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.